What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

Eli Lilly (LLY) is acquiring Verve Therapeutics (VERV) for nearly $1.3 billion, adding Verve's gene therapies targeting heart diseases to its pipeline, including VERVE-102. This acquisition marks Lilly's third targeted M&A deal this year, reflecting its strategic focus on diversifying beyond GLP-1 drugs into cardiovascular, oncology, and neuroscience areas, mirroring a broader trend of increased M&A activity in the pharma/biotech sector in 2025.

Analysis

Eli Lilly (LLY) is actively pursuing strategic diversification beyond its dominant GLP-1 franchise through a series of targeted M&A activities, exemplified by the definitive agreement to acquire Verve Therapeutics (VERV) for approximately $1.3 billion. This deal, expected to close in the third quarter, will incorporate Verve's gene-editing therapies for heart diseases, including the investigational VERVE-102, into Lilly's pipeline. This marks Lilly's third significant acquisition this year, following a $2.5 billion deal for Scorpion Therapeutics' oncology drug STX-478 and a $1 billion deal for SiteOne Therapeutics' pain treatment STC-004, broadening its reach into cardiovascular, oncology, and neuroscience. This M&A strategy aligns with a broader pickup in pharmaceutical and biotech sector M&A in 2025, driven by portfolio expansion, pipeline innovation amidst recent tariff threats, and investor pressure, as seen with Sanofi's $9.5 billion bid for Blueprint Medicines and Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies. Despite strong sales from its GLP-1 drugs Mounjaro and Zepbound, which compete with Novo Nordisk's Ozempic and Wegovy, Lilly's stock performance has been robust, rising 1.7% year-to-date, outperforming the industry's 1.2% decline and the broader market. However, LLY shares trade at a premium valuation with a forward P/E ratio of 30.06, significantly above the industry average of 15.05, though below its five-year mean of 34.54. Compounding this valuation concern, earnings estimates for 2025 have been revised downwards from $23.06 to $21.95 per share, and 2026 estimates from $31.15 to $30.91 per share over the past 60 days, contributing to its current Zacks Rank #3 (Hold).

Key Decisions for Investors

• Investors should recognize Eli Lilly's M&A strategy as a critical long-term initiative to diversify revenue streams and build future growth drivers beyond GLP-1s, though the successful integration of Verve Therapeutics and other acquisitions, along with the progression of their respective pipelines, will be key to realizing value.
• Given the stock's significant outperformance and premium valuation at a 30.06 forward P/E, coupled with recent downward revisions in 2025 and 2026 earnings estimates, investors should carefully assess whether the long-term diversification benefits adequately compensate for the current valuation and near-term earnings pressure.
• It is advisable to monitor the clinical development milestones of newly acquired assets, particularly VERVE-102, and Lilly's ability to sustain momentum in its core GLP-1 market, before making substantial adjustments to existing positions.